Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$7.99
+0.20 (+2.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $604340.15 · quality 43.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.6B
P/E
72.6x
↑EV/EBITDA
25.2x
↑ROE
3.7%
↑Gross Margin
28.0%
↓Debt/Equity
0.48
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.6%
FCF CAGR
—
FCF margin
1.5%
FCF / Net income
0.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.76B · net income $60.0M · FCF $26.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.76B | $1.76B | $1.94B | $2.07B | $1.96B |
| Net Income | $60.0M | $60.0M | $50.5M | $43.6M | $-72.2M |
| EBITDA | $197.3M | $197.3M | $158.8M | $163.6M | $43.1M |
| EPS | 0.11 | 0.11 | 0.09 | 0.08 | -0.13 |
| Gross Margin | 28.0% | 28.0% | 25.6% | 27.3% | 24.1% |
| Operating Margin | 9.3% | 9.3% | 4.4% | 5.1% | 2.2% |
| Net Margin | 3.4% | 3.4% | 2.6% | 2.1% | -3.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.48 | 0.48 | 0.63 | 0.45 | 0.42 |
| Current Ratio | 1.26 | 1.26 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $26.0M | $26.0M | $-76.8M | $604340.15 | $-191.0M |
| Returns | |||||
| ROE | 3.7% | 3.7% | 3.2% | 2.8% | -4.6% |
| Valuation | |||||
| P/E | 72.64 | 72.64 | 54.41 | 77.91 | — |
| EV/EBITDA | 25.16 | 25.16 | 22.44 | 23.88 | 90.06 |
| P/B | 2.75 | 2.75 | 1.75 | 2.15 | 2.25 |
| Growth & Yield | |||||
| Revenue Growth | -9.5% | -9.5% | -6.2% | 5.6% | — |
| EPS Growth | 19.5% | 19.5% | 17.3% | 160.3% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
87.0%
EPS terminal req.
$0.71
Spread vs growth
-67.5%
5Y implied EPS CAGR
51.2%
EPS terminal req.
$0.86
Spread vs growth
-31.7%
10Y implied EPS CAGR
29.0%
EPS terminal req.
$1.38
Spread vs growth
-9.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+47.9%
Start / end P/E
59.6x → 73.6x
EPS bridge
0.09 → 0.11
Residual
+4.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.